Format

Send to

Choose Destination
Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S141-6. doi: 10.1016/j.clml.2015.02.006.

Transformative Clinical Trials in Non-Hodgkin and Hodgkin Lymphomas.

Author information

1
Center for Lymphoma, Massachusetts General Hospital Cancer Center, and Department of Medicine, Harvard Medical School, Boston, MA. Electronic address: jabramson@mgh.harvard.edu.

Abstract

Dramatic progress in the understanding of underlying disease biology and the development of novel therapeutics has yielded a revolution that is poised to transform the face of lymphoma treatment across a broad spectrum of histologies. Ongoing randomized clinical trials are poised to unseat long-entrenched standards of care in diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma, and Hodgkin lymphoma. Emerging treatment approaches are reviewed, including optimization of existing chemoimmunotherapy platforms, development of chemotherapy-sparing immunotherapy for follicular lymphoma, biologically targeted therapy for subsets of diffuse large B-cell lymphoma, and incorporation of novel agents into the treatment of mantle cell lymphoma and peripheral T-cell lymphoma. Novel therapies in early stage trials with future promise of redefining standards of care are also reviewed for non-Hodgkin and Hodgkin lymphomas, including small molecule pathway inhibitors and advances in immunotherapy.

KEYWORDS:

Diffuse Large B-cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Novel Agents; Peripheral T-cell Lymphoma

PMID:
26297267
DOI:
10.1016/j.clml.2015.02.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center